Cs2CoCl4 single crystals exhibit unique negative photoconductivity and volatile resistive switching, paving the way for ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of multiple malignant tumors. To date, toripalimab has been approved for marketing ...

Operation Serpentine provides a unique experience for Delta Force players acting as a ‘raid’. Exclusively a PvE activity, ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...